Investigational drug · Phase 2
Vutiglabridin
Also called: HSG4112
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Knee Osteoarthritis (Knee OA), Parkinson Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "Vutiglabridin"
First trial start
2024
Jul 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vutiglabridin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Knee Osteoarthritis (Knee OA)
- Parkinson Disease
Approved drugs for the same conditions: Parkinson's disease · Osteoarthritis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Vutiglabridin" as an intervention, largest first.
- A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease PatientsCompleted
GlaceumIndustry
NCT06329141 · 99 participants · Start Jul 22, 2024 · Primary completion Dec 16, 2025
Drug: Vutiglabridin; Placebo · For: Parkinson Disease
Sites: Anyang-si, South Korea; Uijeongbu-si, South Korea; Busan, South Korea · 9 sites in all
- A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis PatientsRecruiting
GlaceumIndustry
NCT06845553 · 60 participants (planned) · Start Aug 19, 2025 · Primary completion Jul 31, 2026
Drug: Vutiglabridin; Placebo · For: Knee Osteoarthritis (Knee OA)
Sites: Seongnam-si, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Effect of glabridin on ion transport across primary human bronchial epithelial cells.
Kolski-Andreaco A, Sembrat J, Butterworth MB, et al. · Am J Physiol Cell Physiol 2026
- Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.
Lee HM, Marakkalage KG, Kim SH, et al. · Int J Obes (Lond) 2026
- Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects.
Lee S, Kim HC, Yoon YR, et al. · Br J Clin Pharmacol 2026
- Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes.
Lee HM, Lee JH, Kim SH, et al. · Biomed Pharmacother 2025
- Targeting PON2 with Vutiglabridin Restores Mitochondrial Integrity and Attenuates Oxidative Stress-Induced Senescence.
Heo JW, Kim HH, Lee JH, et al. · Antioxidants (Basel) 2025
- Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease.
An H, Kang S, Shin J, et al. · Mol Neurodegener 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.